Early progression after immune checkpoint inhibition: aligning assessment with disease distribution

Clicks: 4
ID: 333287
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #22 of 22 articles by views in japanese journal of clinical oncology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Standardizing 90-day assessment and including early death as treatment failure could clarify whether disease distribution remains associated with early progression after immune checkpoint inhibition.
Reference Key
openalex_W7223139479 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Murat Kiracı
Journal japanese journal of clinical oncology
Year 2026
DOI
10.1093/jjco/hyag179
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.